These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Genetically engineered animals in drug discovery and development: a maturing resource for toxicologic research. Bolon B Basic Clin Pharmacol Toxicol; 2004 Oct; 95(4):154-61. PubMed ID: 15504150 [TBL] [Abstract][Full Text] [Related]
11. The future of wound healing: pursuing surgical models in transgenic and knockout mice. Reid RR; Said HK; Mogford JE; Mustoe TA J Am Coll Surg; 2004 Oct; 199(4):578-85. PubMed ID: 15454143 [TBL] [Abstract][Full Text] [Related]
12. Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Kruglov AA; Kuchmiy A; Grivennikov SI; Tumanov AV; Kuprash DV; Nedospasov SA Cytokine Growth Factor Rev; 2008; 19(3-4):231-44. PubMed ID: 18502680 [TBL] [Abstract][Full Text] [Related]
13. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha. Edwards CK; Bendele AM; Reznikov LI; Fantuzzi G; Chlipala ES; Li L; Moldawer LL; Mountz JD; Li YY; Dinarello CA Arthritis Rheum; 2006 Sep; 54(9):2872-85. PubMed ID: 16947419 [TBL] [Abstract][Full Text] [Related]
14. Current and future approaches using genetically modified mice in endocrine research. Davey RA; MacLean HE Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E429-38. PubMed ID: 16684850 [TBL] [Abstract][Full Text] [Related]
15. Genetic engineering in the mouse: tuning TNF/TNFR expression. Douni E; Alexiou M; Kollias G Methods Mol Med; 2004; 98():137-70. PubMed ID: 15064438 [TBL] [Abstract][Full Text] [Related]
16. The program for phenotyping of genetically modified animals at AstraZeneca. Berg AL; Bohlooly-Y M Exp Toxicol Pathol; 2006 Jul; 57(5-6):383-4. PubMed ID: 16709449 [TBL] [Abstract][Full Text] [Related]